Emerging clinical evidence suggests that Novera Retatrutide, a combined-action therapy from Novo Nordisk, could offer a significant breakthrough in weight management. Beyond many existing options, Retatrutide impacts both the GLP-1 hormone and GIP, potentially resulting to greater reductions in body